Recruiting

Health & Wellness Coaching

Sponsor:

Mayo Clinic

Code:

NCT07545837

Conditions

Thyroid Gland Follicular Carcinoma

Thyroid Gland Papillary Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Counseling

Interview

Questionnaire Administration

Study Details

Brief summary:

This clinical trial evaluates the impact of a patient-centered health and wellness coaching (HWC) intervention on adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid cancer. Treatment for thyroid cancer often involves surgery, radioactive iodine and/or lifelong levothyroxine with regular monitoring of thyroid stimulating hormone levels. Despite strong survival rates, patients frequently report fatigue, cognitive issues, mood changes, and disruptions in daily life. Treatment burden and psychosocial strain often impair the ability to follow the treatment plan and healthy lifestyle. Studies have shown that HWC motivates patients to take ownership and accountability to perform positive and healthy behavioral changes. HWC may have a positive impact on health-related goal-setting processes and improve self-care and healthcare outcomes in certain settings. It is not yet known how HWC impacts thyroid cancer patients. Incorporating HWC into survivorship care may improve adherence to treatment plans and healthy lifestyle practices in patients with papillary or follicular thyroid cancer.

Conditions

Thyroid Gland Follicular Carcinoma

Thyroid Gland Papillary Carcinoma

Study ID

NCT07545837

Start date

Jun 23, 2026

Status verified date

Jul, 2026

Completion date

Jun 30, 2027

Anticipated

Primary completion date

Jun 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults ≥ 18 years
  • Histologically confirmed papillary or follicular thyroid carcinoma
  • Status post total thyroidectomy ± radioactive iodine therapy
  • Receiving levothyroxine monotherapy (no triiodothyronine \[T3\] or desiccated thyroid products)
  • Thyroid-stimulating hormone (TSH) < 4 uIU/mL at ≥ 3 months post-thyroidectomy
  • English proficiency
  • Ability to provide informed consent

Exclusion Criteria:

  • Medullary or anaplastic thyroid carcinoma
  • Current systemic therapy for thyroid or other cancers
  • Cognitive or psychiatric impairment precluding participation
  • Inability to complete study procedures

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Supportive care (HWC)

Patients attend an initial HWC session over 60 minutes and then attend follow-up HWC sessions over 20-60 minutes each monthly for up to 5 months.

Interventions

Counseling

Attend HWC sessions

Interview

Ancillary studies

Questionnaire Administration

Ancillary studies

Primary outcome measure

  • Recruitment rate [ Time Frame: Up to 1 year ]
  • Retention rate [ Time Frame: At 6 months ]
  • Session completion rates [ Time Frame: Up to 6 months ]
  • Study completion rate [ Time Frame: At baseline and at 6 months ]
  • Intervention fidelity [ Time Frame: Up to 6 months ]

Central Contacts and Locations

Central contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Megan Warner

904-953-0476

Locations

Mayo Clinic in Florida

Recruiting

Jacksonville, Florida, United States, 32224-9980

Contacts

Clinical Trials Referral Office

855-776-0015mayocliniccancerstudies@mayo.edu

Megan Warner

904-953-0476

Principal Investigator:

Abd Moain Abu Dabrh, MB, BCh, MS

More Information

Sponsor

Mayo Clinic

Last update posted

Jul 8, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-07-08.